{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T12:42:32Z","timestamp":1783687352365,"version":"3.55.0"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T00:00:00Z","timestamp":1774915200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T00:00:00Z","timestamp":1779148800000},"content-version":"vor","delay-in-days":49,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Miltenyi Biomedicine"},{"name":"Miltenyi Biomedicne"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-026-44232-x","type":"journal-article","created":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T09:54:39Z","timestamp":1774950879000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Risk attitudes and value of hope: survey results from Japanese hematologists and oncologists treating patients with diffuse large B-cell lymphoma"],"prefix":"10.1038","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9662-5093","authenticated-orcid":false,"given":"Yasuyuki","family":"Arai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy","family":"Bolt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hikaru","family":"Onishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2389-8218","authenticated-orcid":false,"given":"Michael","family":"LoPresti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria","family":"Arguissain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1110-2793","authenticated-orcid":false,"given":"J\u00f6rg","family":"Mahlich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,31]]},"reference":[{"issue":"4","key":"44232_CR1","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1016\/j.jval.2022.01.010","volume":"25","author":"P Neumann","year":"2022","unstructured":"Neumann, P., Garrison, L. & Willke, R. The history and future of the \u201cISPOR value flower\u201d: Addressing limitations of conventional cost-effectiveness analysis. Value Health 25(4), 558\u2013565 (2022).","journal-title":"Value Health"},{"key":"44232_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/03007995.2025.2550347","volume":"41","author":"J Shafrin","year":"2025","unstructured":"Shafrin, J. et al. Caregiver risk preferences for delaying loss of ambulation in Duchenne muscular dystrophy in the United States. Curr. Med. Res. Opin. 41, 1\u201311 (2025).","journal-title":"Curr. Med. Res. Opin."},{"key":"44232_CR3","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.690021","volume":"12","author":"I Jakab","year":"2021","unstructured":"Jakab, I. et al. Patient and payer preferences for additional value criteria. Front. Pharmacol. 12, 690021 (2021).","journal-title":"Front. Pharmacol."},{"key":"44232_CR4","doi-asserted-by":"publisher","first-page":"4199","DOI":"10.2147\/JMDH.S458181","volume":"17","author":"R Fischer","year":"2024","unstructured":"Fischer, R. et al. Healthcare stakeholder perspectives on a value assessment approach for Duchenne Muscular Dystrophy therapies. J. Multidiscip. Healthc. 17, 4199\u20134212 (2024).","journal-title":"J. Multidiscip. Healthc."},{"issue":"1","key":"44232_CR5","doi-asserted-by":"publisher","DOI":"10.1080\/20016689.2021.1981574","volume":"9","author":"J Mahlich","year":"2021","unstructured":"Mahlich, J. & Dheban, S. Bright line or lottery? On significance and value in medical decision making. J. Mark. Access Health Policy 9(1), 1981574 (2021).","journal-title":"J. Mark. Access Health Policy"},{"issue":"5","key":"44232_CR6","doi-asserted-by":"publisher","first-page":"2057","DOI":"10.1093\/jeea\/jvz035","volume":"18","author":"M Dertwinkel-Kalt","year":"2020","unstructured":"Dertwinkel-Kalt, M. & K\u00f6ster, M. Salience and skewness preferences. J. Eur. Econ. Assoc. 18(5), 2057\u20132107 (2020).","journal-title":"J. Eur. Econ. Assoc."},{"key":"44232_CR7","doi-asserted-by":"publisher","first-page":"2093","DOI":"10.2147\/PPA.S248295","volume":"14","author":"B Hauber","year":"2020","unstructured":"Hauber, B., Penrod, J. R., Gebben, D. & Musallam, L. The value of hope: Patients\u2019 and physicians\u2019 preferences for survival in advanced non-small cell lung cancer. Patient Prefer. Adherence 14, 2093\u20132104 (2020).","journal-title":"Patient Prefer. Adherence"},{"issue":"4","key":"44232_CR8","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1377\/hlthaff.2011.1300","volume":"31","author":"DN Lakdawalla","year":"2012","unstructured":"Lakdawalla, D. N. et al. How cancer patients value hope and the implications for cost-effectiveness assessments of high-cost cancer therapies. Health Aff (Millwood) 31(4), 676\u2013682 (2012).","journal-title":"Health Aff (Millwood)"},{"issue":"2","key":"44232_CR9","doi-asserted-by":"publisher","first-page":"217223","DOI":"10.1016\/j.jval.2016.11.028","volume":"20","author":"J Shafrin","year":"2017","unstructured":"Shafrin, J., Schwartz, T. T., Okoro, T. & Romley, J. A. Patient versus physician valuation of durable survival gains: Implications for value framework assessments. Value Health 20(2), 217223 (2017).","journal-title":"Value Health"},{"issue":"10","key":"44232_CR10","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1016\/j.jval.2021.04.1284","volume":"24","author":"S Reed","year":"2021","unstructured":"Reed, S., Yang, J., Gonzalez, J. & Johnson, F. R. Quantifying value of hope. Value Health 24(10), 1511-1519.4 (2021).","journal-title":"Value Health"},{"key":"44232_CR11","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.jpubeco.2016.11.012","volume":"145","author":"D Lakdawalla","year":"2017","unstructured":"Lakdawalla, D., Malani, A. & Reif, J. The insurance value of medical innovation. J. Public Econ. 145, 94\u2013102 (2017).","journal-title":"J. Public Econ."},{"key":"44232_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhealeco.2024.102857","volume":"94","author":"K Mulligan","year":"2024","unstructured":"Mulligan, K., Baid, D., Doctor, J. N., Phelps, C. E. & Lakdawalla, D. N. Risk preferences over health: Empirical estimates and implications for medical decision-making. J. Health Econ. 94, 102857 (2024).","journal-title":"J. Health Econ."},{"key":"44232_CR13","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.jhealeco.2016.04.002","volume":"48","author":"AE Attema","year":"2016","unstructured":"Attema, A. E., Brouwer, W. B., l\u2019Haridon, O. & Pinto, J. L. An elicitation of utility for quality of life under prospect theory. J. Health Econ. 48, 121\u2013134 (2016).","journal-title":"J. Health Econ."},{"key":"44232_CR14","volume-title":"Culture\u2019s Consequences: Comparing Values, Behaviors, Institutions, and Organizations Across Nations","author":"G Hofstede","year":"2001","unstructured":"Hofstede, G. Culture\u2019s Consequences: Comparing Values, Behaviors, Institutions, and Organizations Across Nations (Sage Publications, 2001)."},{"key":"44232_CR15","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/s12962-018-0103-1","volume":"16","author":"J Mahlich","year":"2018","unstructured":"Mahlich, J., Dilokthornsakul, P., Sruamsiri, R. & Chaiyakunapruk, N. Cultural beliefs, utility values, and health technology assessment. Cost Eff. Resour. Alloc. 16, 19 (2018).","journal-title":"Cost Eff. Resour. Alloc."},{"issue":"1","key":"44232_CR16","doi-asserted-by":"publisher","DOI":"10.1080\/20565623.2024.2413801","volume":"10","author":"A Muramatsu","year":"2024","unstructured":"Muramatsu, A. & Kawakami, T. Incidence of hematologic cancer types in Japan by ICD-O-3 code: Analysis of National Cancer Registry. Future Sci. OA. 10(1), 2413801 (2024).","journal-title":"Future Sci. OA."},{"issue":"5","key":"44232_CR17","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0269169","volume":"17","author":"S Tsutsu\u00e9","year":"2022","unstructured":"Tsutsu\u00e9, S., Makita, S., Yi, J. & Crawford, B. Cost drivers associated with diffuse large B-cell lymphoma (DLBCL) in Japan: A structural equation model (SEM) analysis. PLoS ONE 17(5), e0269169 (2022).","journal-title":"PLoS ONE"},{"key":"44232_CR18","unstructured":"Ministry of Health, Labour and Welfare. Statistics of Physicians, Dentists and Pharmacists [Internet]. Tokyo 2020. [cited 2024 Mar 27]. Available from: https:\/\/www.mhlw.go.jp\/toukei\/saikin\/hw\/ishi\/20\/index.html."},{"issue":"16","key":"44232_CR19","doi-asserted-by":"publisher","first-page":"1800","DOI":"10.1182\/blood-2017-03-769620","volume":"130","author":"M Crump","year":"2017","unstructured":"Crump, M. et al. Outcomes in refractory diffuse large B-cell lymphoma: Results from the international SCHOLAR-1 study. Blood 130(16), 1800\u20131808 (2017).","journal-title":"Blood"},{"issue":"5","key":"44232_CR20","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1053\/j.seminhematol.2023.11.007","volume":"60","author":"H Kinoshita","year":"2023","unstructured":"Kinoshita, H., Bollard, C. M. & Toner, K. CD19 CAR-T cell therapy for relapsed or refractory diffuse large B cell lymphoma: Why does it fail?. Semin. Hematol. 60(5), 329\u2013337 (2023).","journal-title":"Semin. Hematol."},{"key":"44232_CR21","unstructured":"Pharmaceuticals and Medical Devices Agency. Optimal Use Guidelines: (Regenerative Medicine Products). Tokyo 2024 [cited 2025 Jul 17]. Available from: https:\/\/www.pmda.go.jp\/review-services\/drug-reviews\/review-information\/ctp\/0011.html."},{"issue":"1","key":"44232_CR22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jebo.2008.04.006","volume":"68","author":"CC Eckel","year":"2008","unstructured":"Eckel, C. C. & Grossman, P. J. Forecasting risk attitudes: An experimental study using actual and forecast gamble choices. J. Econ. Behav. Organ. 68(1), 1\u201317 (2008).","journal-title":"J. Econ. Behav. Organ."},{"issue":"2\u20133","key":"44232_CR23","first-page":"649","volume":"7","author":"B Golsteyn","year":"2009","unstructured":"Golsteyn, B., Heckman, J. & Meijers, H. Gender differences in risk aversion and ambiguity aversion. J. Eur. Econ. Assoc. 7(2\u20133), 649\u2013658 (2009).","journal-title":"J. Eur. Econ. Assoc."},{"key":"44232_CR24","first-page":"227","volume":"7","author":"LA Obaidi","year":"2015","unstructured":"Obaidi, L. A. & Mahlich, J. A potential gender bias in assessing quality of life - A standard gamble experiment among university students. Clinicoecon. Outcomes Res. 7, 227\u2013233 (2015).","journal-title":"Clinicoecon. Outcomes Res."},{"key":"44232_CR25","first-page":"1","volume":"4","author":"U Schaede","year":"2018","unstructured":"Schaede, U. et al. Shared decision-making in prostate cancer treatment in Japan: Patient preferences versus physician perceptions. J. Glob. Oncol. 4, 1\u20139 (2018).","journal-title":"J. Glob. Oncol."},{"issue":"11","key":"44232_CR26","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0111237","volume":"9","author":"R Krammer","year":"2014","unstructured":"Krammer, R. & Heinzerling, L. Therapy preferences in melanoma treatment - Willingness to pay and preference of quality versus length of life of patients, physicians and healthy controls. PLoS ONE 9(11), e111237 (2014).","journal-title":"PLoS ONE"},{"issue":"1","key":"44232_CR27","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1186\/s13561-025-00653-4","volume":"15","author":"S Kasahara","year":"2025","unstructured":"Kasahara, S., Kato, H. & Goto, R. Difference in time and risk preferences: Physicians and general population across genders. Health Econ. Rev. 15(1), 56 (2025).","journal-title":"Health Econ. Rev."},{"key":"44232_CR28","volume":"1","author":"SM Albert","year":"2012","unstructured":"Albert, S. M. & Duffy, J. Differences in risk aversion between young and older adults. Neurosci. Neuroecon. 1, 10.2147\/NAN.S27184 (2012).","journal-title":"Neurosci. Neuroecon."},{"issue":"605","key":"44232_CR29","first-page":"F95","volume":"127","author":"T Dohmen","year":"2017","unstructured":"Dohmen, T., Falk, A., Golsteyn, B., Huffman, D. & Sunde, U. Risk attitudes across the life course. Econom. J. 127(605), F95\u2013F116 (2017).","journal-title":"Econom. J."},{"issue":"4","key":"44232_CR30","first-page":"981","volume":"72","author":"N Jianakoplos","year":"2006","unstructured":"Jianakoplos, N. & Bernasek, A. Financial risk taking by age and birth cohort. South. Econ. J. 72(4), 981\u20131001 (2006).","journal-title":"South. Econ. J."},{"issue":"12","key":"44232_CR31","doi-asserted-by":"publisher","first-page":"1634","DOI":"10.1016\/j.cub.2016.05.017","volume":"26","author":"RB Rutledge","year":"2016","unstructured":"Rutledge, R. B. et al. Risk taking for potential reward decreases across the lifespan. Curr. Biol. 26(12), 1634\u20131639 (2016).","journal-title":"Curr. Biol."},{"issue":"8","key":"44232_CR32","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1016\/j.jval.2025.04.2166","volume":"28","author":"J Hong","year":"2025","unstructured":"Hong, J., Bae, E. Y. & Yu, S. The value of hope in cancer care: Risk preference and heterogeneity in cancer patients and the general public. Value Health 28(8), 1259\u20131267 (2025).","journal-title":"Value Health"},{"key":"44232_CR33","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhealeco.2020.102346","volume":"72","author":"D Lakdawalla","year":"2020","unstructured":"Lakdawalla, D. & Phelps, C. Health technology assessment with risk aversion in health. J. Health Econ. 72, 102346 (2020).","journal-title":"J. Health Econ."},{"issue":"2","key":"44232_CR34","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1016\/j.jval.2020.10.003","volume":"24","author":"DN Lakdawalla","year":"2021","unstructured":"Lakdawalla, D. N. & Phelps, C. E. Health technology assessment with diminishing returns to health: The generalized risk-adjusted cost-effectiveness (GRACE) approach. Value Health 24(2), 244\u2013249 (2021).","journal-title":"Value Health"},{"issue":"8","key":"44232_CR35","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1016\/j.jval.2025.05.005","volume":"28","author":"M Graf","year":"2025","unstructured":"Graf, M. et al. Implementing the generalized risk-adjusted cost-effectiveness model for sickle cell disease: A case study. Value Health. 28(8), 1153\u20131160 (2025).","journal-title":"Value Health."},{"key":"44232_CR36","unstructured":"Institute for Clinical and Economic Review (ICER). Value Assessment Framework, Boston 2023, available at: https:\/\/icer.org\/wp-content\/uploads\/2023\/10\/ICER_2023_2026_VAF_For-Publication_070825.pdf"},{"issue":"1","key":"44232_CR37","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1017\/S0266462317000174","volume":"33","author":"J Mahlich","year":"2017","unstructured":"Mahlich, J., Kamae, I. & Rossi, B. A new health technology assessment system for Japan? Simulating the potential impact on the price of Simeprevir. Int. J. Technol. Assess. Health Care 33(1), 121\u2013127 (2017).","journal-title":"Int. J. Technol. Assess. Health Care"},{"issue":"4","key":"44232_CR38","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1080\/13696998.2020.1716775","volume":"23","author":"I Kamae","year":"2020","unstructured":"Kamae, I., Thwaites, R., Hamada, A. & Fernandez, J. Health technology assessment in Japan: A work in progress. J. Med. Econ. 23(4), 317\u2013322 (2020).","journal-title":"J. Med. Econ."},{"issue":"12","key":"44232_CR39","doi-asserted-by":"publisher","first-page":"e1006","DOI":"10.1200\/JOP.2016.013995","volume":"12","author":"M Bluhm","year":"2016","unstructured":"Bluhm, M. et al. Paradox of prescribing late chemotherapy: Oncologists explain. J. Oncol. Pract. 12(12), e1006\u2013e1015 (2016).","journal-title":"J. Oncol. Pract."},{"key":"44232_CR40","first-page":"1","volume":"4","author":"U Schaede","year":"2018","unstructured":"Schaede, U. et al. Shared decision-making in prostate cancer treatment in Japan: Patient preferences versus physician perceptions. J. Global Oncol. 4, 1\u20139 (2018).","journal-title":"J. Global Oncol."},{"issue":"5","key":"44232_CR41","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1159\/000471795","volume":"35","author":"J Mahlich","year":"2017","unstructured":"Mahlich, J., Matsuoka, S. & Sruamsiri, R. Shared decision making and treatment satisfaction in Japanese patients with Inflammatory Bowel Disease (IBD). Dig. Dis. 35(5), 454\u2013462 (2017).","journal-title":"Dig. Dis."},{"issue":"2","key":"44232_CR42","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1007\/s40744-019-0156-4","volume":"6","author":"J Mahlich","year":"2019","unstructured":"Mahlich, J., Schaede, U. & Sruamsiri, R. Shared decision-making and patient satisfaction in Japanese Rheumatoid Arthritis patients: A new \u2018Preference Fit\u2019 framework for treatment assessment. Rheumatol. Ther. 6(2), 269\u2013283 (2019).","journal-title":"Rheumatol. Ther."},{"key":"44232_CR43","doi-asserted-by":"publisher","DOI":"10.1186\/s12911-020-01355-z","volume":"20","author":"K Nakayama","year":"2020","unstructured":"Nakayama, K. et al. Shared decision making, physicians\u2019 explanations, and treatment satisfaction: A cross-sectional survey of prostate cancer patients. BMC Med. Inform. Decis. Mak. 20, 334 (2020).","journal-title":"BMC Med. Inform. Decis. Mak."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-44232-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-44232-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-44232-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T05:03:47Z","timestamp":1779253427000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-44232-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,31]]},"references-count":43,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["44232"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-44232-x","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,31]]},"assertion":[{"value":"16 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"VA and JM are employees of Miltenyi Biomedicine. HO and ML are employees of INTAGE Healthcare, a contract research company that received funding from Miltenyi Biomedicine to conduct the study in line with the study protocol. All authors have no other relevant affiliations or financial involvement with any other organization or entity with a financial interest in the subject matter or materials discussed in the manuscript apart from those disclosed.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"All individual data are anonymized in the research database to comply with Japanese data protection regulations. Approval from an institutional review board in Japan was obtained prior to conducting the survey.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}],"article-number":"15558"}}